SYMPTOMS | CASE COUNTS | PREVENTION | VACCINE FINDER

---

Mpox, formerly known as monkeypox, is a rare disease caused by an Orthopoxvirus. Persons with mpox typically report having close, sustained physical contact with other people who have mpox. In the recent global outbreak, persons primarily impacted were gay, bisexual, or other men who have sex with men. Anyone who has been in close contact with someone who has mpox can get the illness. The risk to the general public is low.

Symptoms

• Rash that looks like pimples or blisters that can occur in the mouth, genital and anal areas, or other parts of the face and body like the hands, feet, and chest.

• Fever

• Headache

• Muscle and backaches

• Chills

• Exhaustion

• Swollen Lymph Nodes

Case Counts

South Dakota 2023 Case Count: 0

South Dakota 2022 Case Count: 3

U.S. Case Count (CDC)

CDC Mpox Website: Mpox disease information: symptoms, transmission, and treatment.

Prevention

Take the following steps to prevent mpox:

• Avoid close skin-to-skin contact with people who have a rash that looks like mpox

• Do not handle or touch materials such as bedding, towels or clothing of a person with mpox

• Wash your hands often with soap and water

CDC Resources:

• Signs and Symptoms: Mpox symptoms usually start within 3 weeks of exposure to the virus. The illness typically lasts 2-4 weeks. Know the symptoms of mpox and when to contact a healthcare professional.

• How It Spreads

• Testing

• Prevention

  • How to Protect Yourself: Learn the 5 steps that can help you protect yourself from mpox

  • Safer Sex & Social Gatherings

  • Congregate Settings: Considerations for reducing mpox transmission in congregate living settings

• If You’re a Close Contact

• If You Are Sick: Learn what you can do to take care of yourself as you recover and prevent the spread to others

• Vaccines

• What's New & Updated

• Communication Resources
  • Toolkits for Community, Work, and School: Information for Where You Live, Work, Learn, and Play
    • Mpox Toolkit for Schools and Early Care and Education Programs
    • What You Need to Know about Mpox if You are a Teen or Young Adult

Find a vaccine

WEBINARS | HANS | TESTING | VACCINE | TREATMENT | CONTACT

---

 

• Information For Healthcare Professionals

• What Clinicians Need to Know About Mpox

• Infection Control Guidance

• Clinical Guidance

  • Clinical recognition

  • Case Algorithm

  • Close Contact Algorithm

  • Monitoring Exposed Persons

  • Isolation and Prevention Practices for People with Mpox

  • Treatment information

• Clincian FAQs

Webinars

• Mpox 101 Webinar

• Healthcare Webinar | Slides (10-06-2022)

Health Alerts (HANs)

• Mpox Health Alerts

  • HAN 475: Severe Manifestations of Mpox among People who are Immunocompromised
  • HAN 472: Mpox in People with HIV, Children and Adolescents, and People who are Pregnant or Breastfeeding
  • HAN 471: Mpox Testing and Treatment
  • HAN 468: Case-finding Guidance

TESTING

• Testing is currently available at Labcorp, Mayo Clinic Laboratories, Quest Diagnostics, Aegis Sciences, Sonic Healthcare USA, and SD Public Health Laboratory

• Information for Laboratory Personnel

• Mpox Requisition Form

• Mpox FAQ

• Mpox Guidance
  

VACCINE

Jynneos Vaccine-Eligible Persons

• Gay, bisexual, and other men who have sex with men, transgender, or nonbinary people

• People who had skin-to-skin contact with someone in a social network experiencing mpox activity

• People who had any of the following in the past 6 months:
  • Sex at a commercial sex venue

  • Sex in association with a large public event

• Sexual partners of people with the above risks

• People who anticipate experiencing the above risks

• Other persons deemed as having risk of being exposed to mpox per medical provider judgement

• People whose degree of exposure to a mpox case is high or intermediate

NOTE: To maximize vaccine doses given from a vial once opened, SD-DOH advocates persons who may be at increased risk for acquiring mpox, who do not meet the eligibility criteria above, receive vaccine.

• Jynneos Vaccine Information Statement (VIS)
• Jynneos Vaccine Considerations
• Standing Orders

• Storage

• MMWR on Use of Jynneos Vaccine

TREATMENT

The antiviral medication tecovirimat (TPOXX) is available for the treatment of patients with mpox infection under the expanded access investigational new drug (EA-IND). Interested providers should follow the steps below:

• Call the SD-DOH Epidemiology Team at 605-773-3737 to discuss the indication for treatment. Note: The primary indication for treatment has been lesions around the anus and genitals.

• SD-DOH will work with the patient’s medical provider and CDC Mpox Clinical Team for a consultation since TPOXX is only available from the Strategic National Stockpile (SNS).

• Medical providers can anticipate TPOXX delivery from the SNS ~48 hours after the order is placed. There are no supplies of TPOXX pre-positioned in South Dakota.

• Guidance on TPOXX for Treatment (CDC)

• Interim Clinical Treatment Considerations for Severe Manifestations of Mpox (CDC)

CONTACT

If you have questions or would like additional information, please contact the Epidemiology team at 605-773-3737.